Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India

6 Dec 2018

Abstract excerpt

BACKGROUND: Artesunate-sulfadoxine-pyrimethamine (ASSP) is the frontline artemisinin combination therapy (ACT) in India. Random, irrational, subtherapeutic artemisinin doses and self-medication with ACT along with predominance of sulfadoxine-pyrimethamine resistance parasite invoked a strong possibility of emerging artemisinin-resistant malaria parasites. METHODS: This study involved 226 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Pharmaceutical Quality and Counterfeiting

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30535043
DOI: 10.1093/cid/ciy1038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern IndiaPMID 30535043Read ↗

Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India.Semantic proximity Read ↗

Therapeutic efficacy of artemether–lumefantrine in North-Eastern states of India and prevalence of drug resistance-associated molecular markersSemantic proximity Read ↗

Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, IndiaSemantic proximity Read ↗

Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.Semantic proximity Read ↗

Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, India.Semantic proximity Read ↗

Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.Semantic proximity Read ↗

Polymorphisms in pfdhfr and pfdhps genes after five years of artemisinin combination therapy (ACT) implementation from urban Kolkata, India.Semantic proximity Read ↗

Updates on k13 mutant alleles for artemisinin resistance in Plasmodium falciparum.Semantic proximity Read ↗

Genomic characterization of Plasmodium falciparum genes associated with anti-folate drug resistance and treatment outcomes in eastern India: A molecular surveillance study from 2008 to 2017.Semantic proximity Read ↗

Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014-2016.Semantic proximity Read ↗

Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy.Semantic proximity Read ↗

First Detection in West Africa of a Mutation That May Contribute to Artemisinin Resistance Plasmodium falciparumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.